PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩330 per share · Prices as of the 2026-10-02 close
Shinhung, a manufacturer and distributor of dental equipment and materials, posted a sharp decline in net income in 2025 and a net loss attributable to owners in the fourth quarter of 2025, but operating profit and net income showed a clear recovery in the first half of 2026.
In the first quarter of 2026 revenue rose 6.5% and operating profit rose 10.7% year on year, and operating profit jumped to roughly KRW 3.6 billion in the second quarter, extending the recovery.
Net income attributable to owners fell sharply to KRW 2.8 billion in 2025 from KRW 5.2 billion in 2024, and the fourth quarter of 2025 recorded a net loss to owners despite positive operating profit.
The domestic dental and implant industry faces concerns about a structural slowdown amid domestic market saturation and a contracting China market.
The company is carrying out a treasury stock buyback of 100,000 shares (about KRW 1.4 billion) from June 8 to September 7, 2026, while the largest shareholder's stake edged up to the mid-70% range.
New unit chair products, the launch of the YUHANevertis implant, and a dental vitamin platform are cited as factors diversifying revenue.
Shinhung was established in 1964 to manufacture and wholesale dental equipment and materials, and listed on the KOSPI in 1991 as a dental equipment and materials specialist.
Its core product lineup includes unit chairs (treatment tables and chairs), dental alloys, injection needles, and crowns, alongside a distribution business that handles a wide range of consumable dental materials.
Its subsidiaries include Shinhung MST, an implant manufacturer, Seoul Daebu, a financing company that lends to dental practitioners, and DV Service, a dental device repair specialist, giving the group a portfolio spanning manufacturing, distribution, financing and after-sales service.
Unlike a pure implant maker dependent on a single product line, this structure diversifies revenue across the full range of purchases a dental clinic makes for equipment and materials.
In the domestic implant market, the top five players—Osstem Implant, Dentium, DENTIS, DIO and MegaGen Implant—are said to control more than 90% of the market, and Shinhung positions itself less as a direct competitor to these makers and more as a comprehensive dealer combining equipment, consumables and financing services.
More recently, subsidiary Shinhung MST launched the new YUHANevertis implant, expanding its own implant manufacturing lineup. The company has also built a dental vitamin platform and an integrated logistics center to respond to shifting clinic purchasing patterns toward online and consolidated procurement.
Its customer base is centered on dental clinics nationwide, and financing subsidiary Seoul Daebu generates additional stable interest income through loans to practicing dentists.
Under this structure, results depend less on the success of any single product and more on Shinhung's overall share of the dental distribution channel and the expansion of its new product lineup.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩24.5B | ₩1.7B | 6.9% |
| 2025Q3 | ₩24.1B | ₩1.5B | 6.2% |
| 2025Q4 | ₩30.4B | ₩3.2B | 10.5% |
| 2026Q1 | ₩25.2B | ₩800M | 3.2% |
| 2026Q2 | ₩26.3B | ₩3.6B | 13.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩118.2B | ₩10.5B | ₩8.2B | 8.8% | 7.7% | 31.6% |
| 2023 | ₩112.4B | ₩11.4B | ₩9.2B | 10.1% | 8.1% | 23.2% |
| 2024 | ₩101.8B | ₩6.3B | ₩5.2B | 6.2% | 4.5% | 21.8% |
| 2025 | ₩102.6B | ₩7.1B | ₩2.8B | 6.9% | 2.4% | 29.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue fell for three straight years, from KRW 118.2 billion in 2022 to KRW 112.4 billion in 2023 and KRW 101.8 billion in 2024, before edging up to KRW 102.6 billion in 2025.
The operating margin peaked at 8.8% in 2022 and 10.1% in 2023, then fell to 6.2% in 2024 before partially recovering to 6.9% in 2025.
Net income attributable to owners, however, declined for three consecutive years—from KRW 9.2 billion in 2023 to KRW 5.2 billion in 2024 and KRW 2.8 billion in 2025—following a different trajectory than operating profit, suggesting significant swings in non-operating items.
Operating cash flow indeed dropped sharply, from KRW 9.6 billion in 2024 to KRW 1.9 billion in 2025, revealing a gap between the income-statement recovery and cash generation.
On a quarterly basis, after operating profit of KRW 1.49 billion and owners' net income of KRW 0.92 billion in the third quarter of 2025, revenue jumped to KRW 30.35 billion in the seasonally strong fourth quarter with operating profit of KRW 3.17 billion, yet owners' net income flipped to a loss of KRW 0.31 billion.
This illustrates once again how improvements in operating profit have not always translated directly into net income, reflecting volatility in non-operating items.
In the first quarter of 2026, revenue was KRW 25.15 billion with operating profit of KRW 0.81 billion and owners' net income of KRW 0.78 billion, and in the second quarter revenue rose to KRW 26.28 billion with operating profit of KRW 3.64 billion and owners' net income of KRW 3.93 billion—a marked improvement that brought the trailing four-quarter (Q3 2025 to Q2 2026) sum of owners' net income to roughly KRW 5.3 billion.
This trend suggests core profitability has been recovering again in the first half of 2026 following the one-off loss in the fourth quarter of 2025.
Industry participants have raised concerns that the domestic dental and implant sector is entering a structural slowdown, as market saturation at home coincides with a contracting China market and a lack of premium positioning in developed markets.
The top five domestic implant makers—Osstem Implant, Dentium, DENTIS, DIO and MegaGen Implant—are reported to control more than 90% of the market, and competition among them over clinical education and services has driven up costs.
Even market leader Osstem Implant was reported to have seen operating profit fall 31% year on year in a recent quarter, indicating that even the largest players are not immune to profitability pressure.
Dentium, whose China exposure exceeds half of its revenue, has reportedly seen its profitability squeezed as supply prices fell after China's government-led volume-based procurement (VBP) system took effect.
Global market researchers, however, project the dental implant market to expand from roughly USD 5.3 billion in 2025 to about USD 5.75 billion in 2026 and to keep growing at around 7% annually thereafter, suggesting that growth opportunities remain overseas even as the domestic market matures.
On the raw material side, spot prices for certain titanium grades have reportedly risen amid aerospace demand and Chinese export controls, a cost-volatility factor for implant and equipment manufacturing.
As Shinhung leans more toward equipment and consumables distribution than pure implant manufacturing, its exposure to any single product cycle is relatively lower than that of dedicated implant makers, though it still shares the same underlying demand base tied to clinic openings and capital investment across the dental sector.
According to the company's disclosed commentary, the improvement in first-quarter 2026 results was mainly attributed to higher sales of new dental unit chair products and the YUHANevertis implant launched by subsidiary Shinhung MST, along with the company's response to changing consumer purchasing patterns through its dental vitamin platform and integrated logistics center.
Given that operating profit and net income also rose sharply in the second quarter, these new-product and new-business trends appear to have continued through the first half of the year.
On the shareholder-return side, the company's board approved and is currently executing a treasury stock buyback of 100,000 common shares (about KRW 1.4 billion) from June 8 to September 7, 2026, equivalent to roughly 1% of market capitalization.
Changes in the shareholding structure are also notable: as of a May 15, 2026 filing, the largest shareholder group's common share stake stood at 76.01%, up slightly from 75.92% as of the prior filing on May 8, 2026, with affiliate DV Mall shown to have made sequential on-market purchases of common shares from May 11 to 15.
In April 2026 the company also transferred a portion of treasury shares to its employee stock ownership association for the purpose of paying employee bonuses, suggesting a continued policy of balancing employee compensation with shareholder value initiatives.
That said, the extent to which these new product launches or the buyback program will support results over the coming quarters has not yet been confirmed through specific company guidance or investor materials.
As the broader domestic dental industry debates whether it has entered a mature phase, whether Shinhung's recent earnings improvement reflects company-specific new-business effects or a broader industry upturn will require further confirmation from data over the next several quarters.
Shinhung's net income peaked in 2023 and declined for two consecutive years through 2025 before showing a recovery in the first half of 2026, meaning the trailing four-quarter earnings base remains below the levels seen during its strongest earning years.
As a result, multiples comparing the current share price to recent confirmed earnings tend to sit above where they stood when profits were at their peak, which reflects the earnings denominator having shrunk and then begun recovering, rather than necessarily an extreme shift in the share price itself.
The price-to-book ratio sits close to, or at a modest premium to, net asset value, rather than in an extreme range far above or below book.
On the dividend side, the company has a history of paying annual cash dividends, though comparing the attractiveness of its payout ratio or yield to industry peers would require further verification.
Overall, current valuation metrics reflect both the 2025 earnings slowdown and the recovery signals seen in the first half of 2026, and their interpretation may shift depending on how the earnings trajectory settles over the coming quarters.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Both the first and second quarters of 2026 showed year-on-year improvement in operating profit and net income, with second-quarter operating profit of KRW 3.6 billion and owners' net income of KRW 3.9 billion marking the highest levels among the last five quarters.
This suggests core profitability is normalizing again following the fourth-quarter 2025 net loss, though confirmation over additional quarters is needed.
Shinhung's revenue base is spread across equipment, consumables, financing and after-sales service through subsidiaries Shinhung MST (implant manufacturing), Seoul Daebu (financing for dentists), and DV Service (repair).
It has also recently expanded its new-business lineup with the YUHANevertis implant launch, a dental vitamin platform, and an integrated logistics center. This diversified structure may temper revenue volatility compared with reliance on a single product line.
The company has been carrying out a 100,000-share treasury stock buyback from June to September 2026, and the largest shareholder group's stake has also edged higher. Affiliate DV Mall has separately made sequential on-market purchases of common shares. These actions can be read as evidence of the company's stated commitment to enhancing shareholder value.
In 2025, operating profit rose year on year yet net income attributable to owners actually declined, and the fourth quarter posted an owners' net loss despite operating profit of KRW 3.17 billion.
Operating cash flow also fell sharply, from KRW 9.6 billion in 2024 to KRW 1.9 billion in 2025, revealing a gap between reported earnings and cash generation. This volatility in non-operating items reduces the reliability of forward earnings projections.
The domestic dental and implant industry faces concerns about entering a structural slowdown as domestic market saturation coincides with a contracting China market, and even the industry leader reportedly saw a sharp decline in a recent quarter's operating profit.
The top five players control more than 90% of the market, and competition over clinical education and service costs is intensifying. While Shinhung's larger distribution weighting limits its direct exposure, it is not entirely insulated from an industry-wide demand slowdown.
As a small-cap stock with a market capitalization of roughly KRW 0.1 trillion, Shinhung has limited securities-firm coverage, meaning access to market information such as target prices or earnings consensus is relatively thin. This can be a factor contributing to wider price volatility due to information asymmetry.
Detailed information such as segment-level revenue breakdowns is also difficult to confirm from publicly available materials.
There are analyses suggesting the domestic dental and implant market has entered a mature phase, and policy changes in China (the volume-based procurement system) are pressuring industry profitability.
Shinhung's higher weighting toward distribution rather than implant manufacturing provides some buffer, but a prolonged industry-wide downturn could still affect the company.
Reports indicate spot prices for certain titanium grades have risen amid aerospace demand and export controls, which could feed through to cost pressure in implant and medical device manufacturing. Rising labor and logistics costs within the distribution business are additional variables that could affect margins.
Net income declined for three straight years through 2025 despite improving operating profit, and the fourth quarter recorded a net loss, leaving volatility in non-operating items as a factor that raises uncertainty in forecasting results. The sharp drop in operating cash flow in 2025 is another point worth monitoring.
This is the scheduled end date of the 100,000-share (about KRW 1.4 billion) treasury stock buyback program that began June 8, 2026; investors should check disclosures for actual completion and any follow-up cancellation or usage plans.
Investors should check the third-quarter 2026 filing to see whether the operating profit and net income recovery seen in the second quarter continued, and whether non-operating items have stabilized.
It will be worth checking how the cash dividend policy for fiscal year 2026 is decided, given the sharp earnings decline seen in 2025.
It will be important to confirm, once specific figures are disclosed, how much the expanding sales of Shinhung MST's YUHANevertis implant and the dental vitamin platform and integrated logistics center are actually contributing to revenue.
Earnings releases from top domestic implant makers such as Osstem Implant and Dentium should be monitored to gauge whether industry-wide profitability trends and the impact of China's policy changes are persisting.
Shinhung is a KOSPI-listed distribution and consumer-goods company built around the manufacturing and distribution of dental equipment and materials, with a diversified structure that also spans implant manufacturing, financing for dentists, and repair services.
After revenue and net income declined for three consecutive years from 2022 to 2024, revenue edged up slightly in 2025 while net income fell further, and the fourth quarter of 2025 in particular recorded a net loss despite positive operating profit, exposing volatility in non-operating items.
However, both operating profit and net income improved markedly in the first and second quarters of 2026, and on a trailing four-quarter basis (third quarter of 2025 through second quarter of 2026), earnings appear to be rebuilding again.
The company has been broadening its revenue base through new products (unit chairs, the YUHANevertis implant) and new businesses (a dental vitamin platform, an integrated logistics center), while also pursuing shareholder-return and governance-related actions such as a treasury stock buyback and an increase in the largest shareholder's stake.
The domestic dental and implant industry faces structural challenges from concerns about market maturity and a contracting China market, but Shinhung's heavier weighting toward distribution and financing gives it relatively lower exposure to any single product cycle compared with dedicated implant makers.
Investors will want to continue monitoring disclosures to see whether the earnings recovery seen in the first half of 2026 persists in coming quarters and whether non-operating items stabilize.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.